FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
147 letters match. Newest first.
-
DrugsJoin Josie
FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsLevity Inc. dba Levity
FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsMEDVi, LLC dba MEDVi
FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
Medium -
DrugsNewman Clinic, PLLC dba Newman Clinic
FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsNewSelf Limited dba NewSelf
FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
Low -
Drugs24HrDoc, Inc. dba 24HrDoc
FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
Medium -
DrugsAlan Health Technologies Inc. dba Alan
FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
Low -
DrugsDripgym Mobile Parent, LLC dba Amp Health
FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
Low -
DrugsBelle Health LLC dba Belle
FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
Low -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsBluefitMD
FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.
Low -
DrugsDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics
FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
Low -
DrugsAspen Aesthetics dba Fifty 410
FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
Low -
DrugsFitRX, LLC dba FitRx
FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
Medium -
DrugsGenesis Health International Inc. dba Genesis
FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk -
DrugsPQ Pharmacy, LLC
FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.
High risk -
DrugsChengdu Brilliant Biopharmaceutical Co., Ltd.
FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.
High risk -
Drugsmotionpharmacy.com
FDA warns motionpharmacy.com over selling unapproved and misbranded prescription drugs online.
High risk -
Drugscheaptrustedpharmacy.com
cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.
High risk -
DrugsGet.Fit.Medical, LLC dba Get.Fit.Medical
FDA warned Get.Fit.Medical that its website sold compounded sildenafil, tadalafil, semaglutide and tirzepatide with false 'generic' claims.
High risk -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsExpert Aesthetics
FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.
Low -
DrugsHealthy Living Clinic
FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.
Low -
DrugsHims & Hers Health, Inc. dba Hers
FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
Medium -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsFitRX, LLC dba Zealthy
FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.
Medium -
DrugsLean Dreams LLC dba LeanDreams
FDA warned LeanDreams over website claims that compounded semaglutide and tirzepatide match FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound.
Low -
Drugsybycmeds
FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.
Medium -
DrugsiVisitDoc, Inc. dba iVisitDoc
FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.
Medium -
DrugsTry Nova
FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.
Low -
DrugsLovely Meds, Inc. dba Lovely Meds
FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.
Low -
DrugsThe HCG Institute
FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.
High risk -
DrugsVitals RX
FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.
Medium -
DrugsTuyo Health, Inc. dba Tuyo Health
FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.
Medium -
DrugsLas Villas Health Care LLC dba Villas Health
FDA warned Villas Health over website claims for compounded semaglutide and sildenafil, calling the drugs misbranded and unapproved.
High risk -
DrugsLyfe Rx
Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.
Low -
DrugsJulyMD
FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.
High risk -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsSprout Health Partners LLC dba Sprout Health
FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
Low -
DrugsMaster Pharmaceuticals Group
FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
High risk -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsHealBerry
FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
Medium -
DrugsReset IV, LLC dba Reset IV
FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
Medium -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low